Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Psoriasis

This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing.

This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing of AMG 827 for up to 362 weeks.

Inclusion Criteria:

• Subject was randomized into Study 20090062 and completed the week 16 evaluation.

Exclusion Criteria:

• Subject had any Serious Adverse Event (SAE) reported during Study 20090062 that was considered possibly related to IP.
• Subject experienced an adverse event in Study 20090062 that, in the opinion of the investigator, could cause extension of treatment to be detrimental to the subject.